GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Apollon Formularies PLC (AQSE:APOL) » Definitions » Profitability Rank

Apollon Formularies (AQSE:APOL) Profitability Rank : 0 (As of Jun. 2023)


View and export this data going back to . Start your Free Trial

What is Apollon Formularies Profitability Rank?

Apollon Formularies has the Profitability Rank of 0.

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is based on these factors:

1. Operating Margin %
2. Piotroski F-Score
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank

Apollon Formularies's Operating Margin % for the quarter that ended in Jun. 2023 was -839.58%. As of today, Apollon Formularies's Piotroski F-Score is 4.


Competitive Comparison of Apollon Formularies's Profitability Rank

For the Drug Manufacturers - Specialty & Generic subindustry, Apollon Formularies's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Apollon Formularies's Profitability Rank Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Apollon Formularies's Profitability Rank distribution charts can be found below:

* The bar in red indicates where Apollon Formularies's Profitability Rank falls into.



Apollon Formularies Profitability Rank Calculation

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Apollon Formularies has the Profitability Rank of 0.

Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.

Profitability Rank is based on these factors:

1. Operating Margin %

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Apollon Formularies's Operating Margin % for the quarter that ended in Jun. 2023 is calculated as:

Operating Margin %=Operating Income (Q: Jun. 2023 ) / Revenue (Q: Jun. 2023 )
=-0.403 / 0.048
=-839.58 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

2. Piotroski F-Score

The zones of discrimination were as such:

Good or high score = 8 or 9
Bad or low score = 0 or 1

Apollon Formularies has an F-score of 4 indicating the company's financial situation is typical for a stable company.

3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.

4. Consistency of the profitability

5. Predictability Rank


Apollon Formularies Profitability Rank Related Terms

Thank you for viewing the detailed overview of Apollon Formularies's Profitability Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Apollon Formularies (AQSE:APOL) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
6 Hope Street, Quayside House, Castletown, IMN, IM9 1AS
Apollon Formularies PLC is a London, England and Jamaican based medical cannabis pharmaceutical company specialising in research and treatment of patients with cancer and chronic pain. It is engaged in investing by seeking to acquire a direct and/or indirect interest in projects and assets in the agriculture and logistics sectors and the medicinal cannabis sector. The company focus on opportunities in Africa and Europe. It has created proprietary hybrid medical cannabis pharmaceutical strains, technology, formulations, and treatment products.

Apollon Formularies (AQSE:APOL) Headlines

From GuruFocus

FPA Capital Fund Q1 2013 Commentary

By Holly LaFon Holly LaFon 04-24-2013

FPA Capital Fund new buys in Q2 2015

By Tiziano Frateschi Tiziano Frateschi 07-14-2015

Apollo Education Group Is a Value Trap

By OPM Insights Nelson Hsu 10-15-2015

Richard Pzena Reduces APOL as Phoenix Rises for Others

By Sally Jones Sally Jones 03-11-2013

5 Stocks Trading Near Their Historical Low P/S Ratios

By Holly LaFon Holly LaFon 04-11-2012

FPA Capital Fund Comments on Apollo Education Group

By Holly LaFon Holly LaFon 02-09-2016

Apollo Group Inc. Reports 10-Q Quarterly Operating Results

By gurufocus gurufocus 06-26-2012

Weekly Guru Bargains Highlights: APOL, GNW, BTU, NIHD, OKE

By GuruFocus GuruFocus 06-30-2012

Valuing Donald Yacktman's Portfolio: The Peter Lynch Fair Value

By Holly LaFon Holly LaFon 07-02-2012

FPA Capital Fund Comments on For-Profit Education Stocks

By Holly LaFon Holly LaFon 12-09-2015